循环Syndecan-1与组织因子途径抑制物作为内皮功能障碍生物标志物可预测烧伤患者死亡率
这项队列研究纳入2013—2017年某区域烧伤中心收治的烧伤患者,入院4小时内采血用ELISA检测血浆SDC-1与TFPI,主要终点为30天住院死亡率。158例中74例符合纳入标准,总死亡率20.3%。死亡患者入院SDC-1与TFPI均显著更高;SDC-1>34 ng/mL与死亡风险升高32倍相关(OR 32.65,95%CI 2.67-399.78,P=0.006),AUROC 0.92;TFPI与9倍风险相关(OR 9.59,95%CI 1.02-89.75,P=0.002),AUROC 0.68。作者提出入院检测SDC-1识别高危烧伤患者,但需更大样本进一步验证。
要点
- 烧伤患者入院4小时内血浆SDC-1>34 ng/mL与30天死亡风险升高32倍相关(OR 32.65,95%CI 2.67-399.78,P=0.006)。
- SDC-1预测30天死亡的AUROC为0.92,原文称其为强预测指标;TFPI的AUROC为0.68,原文称其为尚可的预测指标。
- TFPI升高与30天死亡风险升高9倍相关(OR 9.59,95%CI 1.02-89.75,P=0.002)。
- 死亡患者入院时SDC-1与TFPI均显著高于存活者;总死亡率为20.3%(74例中)。
- 作者建议入院时检测SDC-1以识别高死亡风险烧伤患者,但明确需更大样本进一步研究验证。
适用人群与场景
- 2013—2017年某区域烧伤中心收治的烧伤患者,158例中74例符合纳入标准。
- 纳入患者以男性为主,中位年龄41.5岁,中位烧伤TBSA 20.5%。
诊断标准与关键阈值
- 入院4小时内采血,ELISA法检测血浆SDC-1与TFPI。
- SDC-1阈值>34 ng/mL用于区分30天死亡高风险(OR 32.65,95%CI 2.67-399.78)。
处置流程与药物剂量
- 原文未提及基于SDC-1或TFPI的具体处置流程或药物方案。
- 作者提议入院时检测SDC-1以识别高死亡风险烧伤患者,但属研究建议,需更大样本验证。
红旗征与不能漏的情况
- 入院SDC-1>34 ng/mL提示30天死亡风险显著升高(OR 32.65,95%CI 2.67-399.78),原文未给出对应的具体处理措施。
- 入院TFPI升高与30天死亡风险升高相关(OR 9.59,95%CI 1.02-89.75),原文未给出对应的具体处理措施。
研究设计与关键结果
- 研究类型:队列研究;单中心(某区域烧伤中心);158例中74例符合纳入标准;2013—2017年收治的烧伤患者。
- 主要终点为30天住院死亡率,总体死亡率为20.3%。
- 死亡患者入院SDC-1与TFPI显著高于存活者。
- SDC-1>34 ng/mL与死亡风险升高32倍相关(OR 32.65,95%CI 2.67-399.78,P=0.006),AUROC 0.92。
- TFPI与死亡风险升高9倍相关(OR 9.59,95%CI 1.02-89.75,P=0.002),AUROC 0.68。
证据类型、等级与局限
- 证据类型:单中心队列研究。
- 局限:单中心、样本量小(74例符合纳入标准)、作者明确需更大样本进一步研究验证。
对床旁实践的改变
- 可考虑在烧伤患者入院4小时内检测血浆SDC-1,辅助识别30天死亡高风险患者(阈值>34 ng/mL,OR 32.65)。
- SDC-1的AUROC为0.92,原文称其为强预测指标;TFPI的AUROC为0.68,预测能力有限。
- 上述为单中心小样本研究结论,作者明确需更大样本验证,不能据此作为常规决策阈值。
- 原文未提及基于生物标志物结果改变治疗的具体做法。
指南或共识出处
- 原文未提及指南或共识出处;文献来源为PubMed(Shock)。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: The aim of this study is to evaluate the association between burn injury and admission plasma levels of Syndecan-1 (SDC-1) and Tissue Factor Pathway Inhibitor (TFPI), and their ability to predict 30-day mortality.
BACKGROUND: SDC-1 and TFPI are expressed by vascular endothelium and shed into the plasma as biomarkers of endothelial damage. Admission plasma biomarker levels have been associated with morbidity and mortality in trauma patients, but this has not been well characterized in burn patients.Methods: This cohort study enrolled burn patients admitted to a regional burn center between 2013 and 2017. Blood samples were collected within 4 h of admission and plasma SDC-1 and TFPI were quantified by ELISA. Demographics and injury characteristics were collected prospectively. The primary outcome was 30-day in-hospital mortality.
RESULTS: Of 158 patients, 74 met inclusion criteria. Most patients were male with median age of 41.5 years and burn TBSA of 20.5%. The overall mortality rate was 20.3%. Admission SDC-1 and TFPI were significantly higher among deceased patients. Plasma SDC-1 >34 ng/mL was associated with a 32-times higher likelihood of mortality [OR: 32.65 (95% CI, 2.67-399.78); P = 0.006] and a strong predictor of mortality (area under the ROC [AUROC] 0.92). TFPI was associated with a nine-times higher likelihood of mortality [OR: 9.59 (95% CI, 1.02-89.75); P = 0.002] and a fair predictor of mortality (AUROC 0.68).
CONCLUSIONS: SDC-1 and TFPI are associated with a higher risk of 30-day mortality. We propose the measurement of SDC-1 on admission to identify burn patients at high risk of mortality. However, further investigation with a larger sample size is warranted.
参考来源
- Keyloun JW, Le TD, Pusateri AE, et al. Circulating Syndecan-1 and Tissue Factor Pathway Inhibitor, Biomarkers of Endothelial Dysfunction, Predict Mortality in Burn Patients. Shock. 2021. PMID: 33394974. doi:10.1097/SHK.0000000000001709
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。